

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number  
**WO 02/074286 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/70**, 31/4468
- (21) International Application Number: PCT/US02/07701
- (22) International Filing Date: 15 March 2002 (15.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/276,837 16 March 2001 (16.03.2001) US
- (71) Applicant: **ALZA CORPORATION** [US/US]; 1900 Charleston Road, M10-3, P.O. Box 7210, Mountain View, CA 94039-7210 (US).
- (72) Inventors: **VENKATRAMAN, Subramanian, S.**; 3165 Maddux Drive, Palo Alto, CA 94303 (US). **LI, Shaoling**; 793 Mahogany Lane, Sunnyvale, CA 94086 (US). **GALE, Robert, M.**; 1276 Russell Avenue, Los Altos, CA 94024 (US). **STEPIC, Jane**; 1620 Gover Lane, San Carlos, CA 94070 (US). **VAN OSDOL, William, W.**; 1662 Cornell Drive, Mountain View, CA 94040 (US).
- (74) Agents: **DATE, Vandana et al.**; 1900 Charleston Road, M10-3, P.O. Box 7210, Mountain View, CA 94039-7210 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TRANSDERMAL PATCH FOR ADMINISTERING FENTANYL



(57) Abstract: A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.

WO 02/074286 A1



## TRANSDERMAL PATCH FOR ADMINISTERING FENTANYL

**Field of the Invention**

5

**[0001]** The present invention relates to a method and a patch for the transdermal administration of fentanyl and analogs thereof for analgetic purposes. In particular, the invention relates to a subsaturated patch for administering fentanyl and analogs thereof to a subject through skin over an  
10 extended period of time.

**Background of the Invention**

**[0002]** Fentanyl and analogs thereof, such as alfentanil, carfentanil,  
15 lofentanil, remifentanil, sufentanil, trefentanil and the like, are powerful synthetic opioids which have demonstrated utility in both human and veterinary medicine. In human medicine, alfentanil, fentanyl, remifentanil and sufentanil have been granted regulatory approval for use as general anesthetics. A fentanyl containing lollipop for oral transmucosal administration  
20 and a fentanyl containing transdermal patch have also been approved as analgesics for use in the treatment of chronic pain.

**[0003]** The transdermal administration of these compounds for the treatment of both acute and chronic pain has been suggested and there are  
25 numerous patents describing various ways of transdermally administering fentanyl and analogs thereof. The following patents U.S. Patent Nos. 4,466,953; 4,470,962; 4,588,580; 4,626,539; 5,006,342; 5,186,939; 5,310,559; 5,474,783; 5,656,286; 5,762,952; 5,948,433; 5,985,317; 5,958,446; 5,993,849; 6,024,976; 6,063,399 and 6,139,866 are believed to be  
30 representative and are incorporated herein by reference. These patents disclose that fentanyl can be administered from a topically applied ointment or cream or from a transdermal patch.



[0004] A transdermal patch is typically a small adhesive bandage that contains the drug to be delivered and these bandages can take several forms. The simplest type is an adhesive monolith comprising a drug-containing reservoir disposed on a backing. The reservoir is typically formed from a pharmaceutically acceptable pressure sensitive adhesive but, in some cases, can be formed from a non-adhesive material, the skin-contacting surface of which is provided with a thin layer of a suitable adhesive. The rate at which the drug is administered to the patient from these patches can vary due to normal person-to-person and skin site-to-skin site variations in the permeability of skin to the drug.

[0005] More complex patches are multilaminate or liquid reservoir types of patches in which a drug release-rate controlling membrane is disposed between the drug reservoir and the skin-contacting adhesive. This membrane, by decreasing the in vitro release rate of drug from the patch, serves to reduce the effects of variations in skin permeability. This type of patch is generally preferred when a highly potent drug is being administered but has the disadvantage of usually having to cover a larger area of skin than a monolithic patch to achieve the same drug administration rate.

[0006] The drug reservoirs of transdermal patches can have the drug either completely dissolved in the reservoir (subsaturated patches, see e.g., U.S. Pat. Nos., 4,704,282; 4,725,439; 4,867,982; 4,908,027; 5,004,610; 5,152,997; 5,164,190; 5,342,623; 5,344,656; 5,364,630; 5,462,745; 5,633,008 and 6,165,497) or can contain an excess of undissolved drug over the saturation concentration (depot patches). Because transdermal patches deliver drug by diffusion through the skin, the delivery rate of the drug from the patch is governed by Fick's law and is proportional to the level of saturation of the drug in the reservoir.

[0007] In a depot patch, the excess drug allows the reservoir to remain saturated with the drug after the patch is applied and it can deliver the drug at the greatest rate for as long as the excess is present. A subsaturated patch, however, will typically exhibit a continuous decrease in the degree of



saturation of the drug in the reservoir and the administration rate of the drug will tend to decrease continuously during use. Thus, depot patches would be preferred where a relatively constant drug administration rate is desired, but the presence of undissolved drug or other constituents in a patch can cause stability and other problems during storage and use.

[0008] Fentanyl and analogs thereof are potent opioids having relatively narrow therapeutic indices. Being potent means that relatively low concentrations of the drug in the blood are sufficient to produce the desired effect. Having a narrow therapeutic index means that the therapeutic effect is obtained only over a narrow range of concentrations; concentrations below the range being ineffective and concentrations above the range being associated with serious, and in the case of opioids, potential lethal side effects. This combination of characteristics, coupled with the patient-to-patient variations in response to opioid analgesics, dictates extreme caution in the administration of opioid drugs.

[0009] Because of the wide variations in individual pharmacokinetic (e.g., drug clearance rates) and pharmacodynamic response to opioids (e.g., the subjective nature of pain and the danger associated with overdose), patients typically need to be titrated upwards to determine the appropriate dose. This means that a patient is initiated at a dose that is expected to be safe and the dose is gradually increased until adequate analgesia is obtained. Because with time, both tolerance to opioids and increased severity of pain may occur, doses may be subsequently increased and/or supplemented with doses of other analgesics for the management of pain. In addition, some patients will require the rescue use of another opioid for the treatment of episodes of breakthrough pain along with their baseline treatment with transdermal opioids.

30

[00010] Although the analgetic transdermal administration of fentanyl and analogs thereof has been widely suggested in the prior art, using transdermal patches of the various types described above, only one such product has actually received regulatory approval in the United States. This



product, DURAGESIC<sup>®</sup>, is a patch that administers fentanyl for 3 days and is indicated for the treatment of chronic pain, as opposed to post-operative or other acute pain. A copy of the labeling describing this patch and its use is incorporated by reference herein (Physicians Desk Reference, 56<sup>th</sup> Edition, 2002, pages 1786-1789). The DURAGESIC<sup>®</sup> fentanyl patch is intended to be sequentially removed and replaced with a fresh patch at the end of each 3 day period to provide relief from chronic pain and it is contemplated that doses may be increased over time and that concurrent use of other analgesics may occur to deal with breakthrough pain.

10

[00011] Because of fentanyl's high potency and narrow therapeutic index, DURAGESIC<sup>®</sup> fentanyl system was designed as a rate controlled, liquid reservoir, depot patch of the type described in Examples 1-4 of US patent 4,588,580.

15

[00012] We have now discovered that fentanyl and analogs thereof can be safely and analgetically effectively delivered over periods of at least 3 days from non-rate controlled, monolithic, subsaturated patches having the characteristics hereinafter described. As a result, fabrication of the patch is simplified, stability of the patch improved and a more comfortable, patient friendly patch provided.

20

[00013] We have also provided a non-rate controlled, monolithic subsaturated patch that is bioequivalent or pharmacologically equivalent to the liquid reservoir, rate-controlled, depot DURAGESIC<sup>®</sup> transdermal fentanyl patch.

25

#### Definitions

[00014] In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below. As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

30



**[00015]** As used herein, the term "an analog of fentanyl" (hereafter referred to as "analog") refers to extremely potent and effective analgesics such alfentanil, carfentanil, lofentanil, remifentanil, sufentanil, trefentanil, and the like.

5

**[00016]** As used herein, the term "drug" refers to fentanyl and analogs thereof.

**[00017]** As used herein, the term "subsaturated patch" refers to patch wherein the concentration of the drug is below its solubility limit. The drug reservoir comprises a single phase polymeric composition, free of undissolved components, wherein the drug and all other components are present at concentrations no greater than, and preferably less than, their saturation concentrations in the reservoir.

15

**[00018]** As used herein, the term "single phase polymeric composition" refers to a composition in which the drug and all other components are solubilized in a polymer and are present at concentrations no greater than, and preferably less than, their saturation concentrations in the reservoir such that there are no undissolved components present in the composition over a substantial portion of the administration period; wherein all the components in combination with the polymer form a single phase.

20

**[00019]** As used herein, the term "component" refers to an element within the drug reservoir, including, but not limited to, a drug as defined above, additives, permeation enhancers, stabilizers, dyes, diluents, plasticizer, tackifying agent, pigments, carriers, inert fillers, antioxidants, excipients, gelling agents, anti-irritants, vasoconstrictors and the like.

25

**[00020]** As used herein, a "rate controlling membrane" refers to a drug release-rate controlling membrane as discussed above.

30



[00021] A "DURAGESIC® fentanyl patch" refers to a fentanyl patch as discussed above (see also Physicians Desk Reference, 56<sup>th</sup> Edition, 2002, pages 1786-1789).

5 [00022] As used herein, the term " $C_{\max}$ " refers to the peak blood or plasma concentration of the drug, i.e., fentanyl or the analog thereof.

[00023] As used herein, the term "standardized  $C_{\max}$  (ng/ml-cm<sup>2</sup>)" refers to the  $C_{\max}$  (ng/ml) per unit area (cm<sup>2</sup>) of the active drug delivery area of the  
10 system, e.g., the area of the drug reservoir.

[00024] As used herein, the term "normalized  $C_{\max}$  (ng/ml-(mg/h))" refers to the  $C_{\max}$  (ng/ml) divided by the rate of the drug administered (mg/h).

15 [00025] As used herein, the term "steady state drug flux" refers to the drug flux (in vitro and in vivo) in the range of 1 to 20  $\mu\text{g/h-cm}^2$  over a substantial portion of the administration period.

[00026] As used herein, the term "bioavailability", refers to the rate and  
20 extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. The rate and extent are established by the pharmacokinetic-parameters, such as, the area under the blood or plasma drug concentration-time curve (AUC) and the peak blood or plasma concentration ( $C_{\max}$ ) of the drug.

25 [00027] Two different products are considered to be "bioequivalent" if they produce substantially the same pharmacokinetic effects when studied under similar experimental conditions. Bioequivalence may be demonstrated through several in vivo and in vitro methods. These methods, in descending  
30 order of preference, include pharmacokinetic, pharmacodynamic, clinical and in vitro studies. In particular, bioequivalence is demonstrated using pharmacokinetic measures such as the area under the blood or plasma drug concentration-time curve (AUC) and the peak blood or plasma concentration



( $C_{\max}$ ) of the drug, using statistical criteria as described in greater detail hereinafter.

[00028] Two different products are considered to be "pharmacologically equivalent" if they produce substantially the same therapeutic effects when studied under similar experimental conditions, as demonstrated through several in vivo and in vitro methods as described in greater detail hereinafter. Therapeutic effects depend on various factors, such as, potency of the drug, the solubility and diffusivity of the drug in the skin, thickness of the skin, concentration of the drug within the skin application site, concentration of the drug in the drug reservoir, and the like, as described in greater detail hereinafter. In general, pharmacological equivalence is demonstrated using measures such as the peak blood or plasma concentration of the drug normalized for the rate of drug administered (i.e. normalized  $C_{\max}$  as defined above) and the peak blood or plasma concentration of the drug standardized per unit area of the active drug delivery area of the system (i.e. standardized  $C_{\max}$  as defined above).

[00029] When comparing two different products whose drug administration rate is proportional to the size of the patch, bioequivalence or pharmacological equivalence may be established either by normalizing the peak blood or plasma concentration of the drug ( $C_{\max}$ ) for the rate of drug administered (normalized  $C_{\max}$ ), or by standardizing the peak blood or plasma concentration of the drug ( $C_{\max}$ ) per unit area of the active drug delivery area of the system (standardized  $C_{\max}$ ). However, when comparing two different products having different drug administration rate per unit area, it is necessary to normalize the peak blood or plasma concentration of the drug ( $C_{\max}$ ) on the basis of the rate of drug administered to establish bioequivalence or pharmacological equivalence.

30

### Summary of the Invention

[00030] The present invention provides a method and a patch for transdermal delivery of fentanyl and analogs thereof for analgetic purposes, to



a subject through skin over an extended period of time. In particular, the present invention provides a non-rate controlled, monolithic, subsaturated patch for transdermal delivery of fentanyl and analogs thereof at an administration rate sufficient to induce and maintain analgesia for at least  
5 three days. In preferred embodiments, the drug is fentanyl, preferably, base form of fentanyl. In additionally preferred embodiments, the drug is sufentanil, preferably the base form of sufentanil.

**[00031]** In another aspect, the present invention provides a non-rate  
10 controlled, monolithic subsaturated patch that is bioequivalent to the liquid reservoir, rate-controlled, depot DURAGESIC® fentanyl patch. In an alternative aspect, the present invention provides a non-rate controlled, monolithic subsaturated patch that is pharmacologically equivalent to the liquid reservoir, rate-controlled, depot DURAGESIC® fentanyl patch.

15

**[00032]** In an additional aspect, the invention pertains to a transdermal patch for administering drug through the skin comprising: (a) a backing layer; and (b) a reservoir disposed on the backing layer, at least the skin contacting surface of the reservoir being adhesive; wherein the reservoir comprises a  
20 *single phase polymeric composition free of undissolved components* containing an amount of the drug sufficient to induce and maintain analgesia for at least three days.

**[00033]** These and other embodiments of the present invention will  
25 readily occur to those of ordinary skill in the art in view of the disclosure herein.

#### Brief Description of the Figures

30 **[00034]** Figure 1 illustrates a cross-section through a schematic, perspective view of one embodiment of transdermal therapeutic system according to this invention.



[00035] Figure 2 illustrates a cross-section view through another embodiment of this invention.

[00036] Figure 3 illustrates the in vitro transdermal flux of various fentanyl patches.

[00037] Figure 4 illustrates the in vitro transdermal flux of various fentanyl and sufentanil patches.

[00038] Figure 5 illustrates the in vitro transdermal flux of various fentanyl and sufentanil patches.

[00039] Figure 6 illustrates the in vitro transdermal flux of various fentanyl and sufentanil patches as a function of drug loading.

[00040] Figure 7 illustrates serum fentanyl concentrations following transdermal application of various fentanyl patches for 72 hours, over a 96 hour period post application.

[00041] Figure 8 illustrates serum fentanyl concentrations following transdermal application of various fentanyl patches for 72 hours, over a 120 hour period post application.

#### Detailed Description of the Invention

[00042] The practice of the present invention will employ, unless otherwise indicated, conventional methods used by those in pharmaceutical product development within those of skill of the art. Such techniques are explained fully in the literature. See, e.g., Patini, G.A. and Chein, Y.W., Swarbrick, J. and Boylan, J.C., eds, Encyclopedia of Pharmaceutical Technology, New York: Marcel Dekker, Inc., 1999 and Gale, R., Hunt, J. and Prevo, M., Mathiowitz, E., ed, Encyclopedia of Controlled Drug Delivery Patches, Passive, New York: J Wiley & Sons, Inc, 1999.



[00043] All patents, patent applications, and publications mentioned herein, whether supra or infra, are hereby incorporated by reference in their entirety.

5

## Modes of Carrying Out the Invention

[00044] The present invention provides a method and a patch for transdermal delivery of fentanyl and analogs thereof for analgetic purposes, to a subject through skin over an extended period of time. In particular, the  
10 present invention provides a non-rate controlled, monolithic, subsaturated patch for transdermal delivery of fentanyl and analogs thereof at a rate and in an amount sufficient to induce and maintain analgesia over a period of at least three days, and up to 7 days to a patient in need thereof.

15 [00045] Referring now to Figures 1 and 2, a preferred embodiment of the transdermal monolithic patch 1 according to this invention comprises a backing layer 2, a drug reservoir 3 disposed on the backing layer 2, wherein at least the skin contacting surface 4 of the reservoir 3 is adhesive, and a peelable protective layer 5. The reservoir 3 comprises a single phase  
20 polymeric composition in which the drug and all other components are present at concentrations no greater than, and preferably less than, their saturation concentrations in the reservoir 3. This produces a composition in which no undissolved components are present. In preferred embodiments, the reservoir 3 is formed from a pharmaceutically acceptable adhesive.

25

[00046] Referring now to Figure 2, the reservoir 3 is formed from a material that does not have adequate adhesive properties. In this embodiment of a monolithic patch 1, the skin contacting surface of the reservoir 4 may be formulated with a thin adhesive coating 6. The reservoir 3  
30 is a single phase polymeric composition as described earlier.

[00047] The backing layer 2 may be a breathable or occlusive material comprising fabric, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyurethane, polyester, ethylene vinyl acetate (EVA), polyethylene



terephthalate, polybutylene terephthalate, coated paper products, aluminum sheet and the like, and a combination thereof. In preferred embodiments, the backing layer comprises low density polyethylene (LDPE) materials, medium density polyethylene (MDPE) materials or high density polyethylene (HDPE) materials, e.g., SARANEX (Dow Chemical, Midland, MI). The backing layer may be a monolithic or a multilaminate layer. In preferred embodiments, the backing layer is a multilaminate layer comprising nonlinear LDPE layer/linear LDPE layer/nonlinear LDPE layer. The backing layer has a thickness of about 0.012 mm (0.5 mil) to about 0.125 mm (5 mil); preferably 0.025 mm (1 mil) to about 0.1 mm (4 mil); more preferably 0.0625 mm (1.5 mil) to about 0.0875 mm (3.5 mil).

**[00048]** The drug reservoir 3 is disposed on the backing layer, wherein at least the skin contacting surface of the reservoir is adhesive. The reservoir 3 may be formed from standard materials as known in the art. For example, the drug reservoir is formed from a polymeric material in which the drug has reasonable solubility for the drug to be delivered within the desired range, such as, a polyurethane, ethylene/vinyl acetate copolymer (EVA), polyacrylate, styrenic block copolymer, and the like. In preferred embodiments, the reservoir 3 is formed from a pharmaceutically acceptable pressure sensitive adhesive, preferably a polyacrylate or a styrenic block copolymer-based adhesive, as described in greater detail below.

**[00049]** The adhesive reservoir 3 or the adhesive coating 6 is formed from standard pressure sensitive adhesives known in the art. Examples of pressure sensitive adhesives include, but are not limited to, polyacrylates, polysiloxanes, polyisobutylene (PIB), polyisoprene, polybutadiene, styrenic block polymers, and the like. Examples of styrenic block copolymer-based adhesives include, but are not limited to, styrene-isoprene-styrene block copolymer (SIS), styrene-butadiene-styrene copolymer (SBS), styrene-ethylenebutene-styrene copolymers (SEBS), and di-block analogs thereof.

**[00050]** The acrylic polymers are comprised of a copolymer or terpolymer comprising at least two or more exemplary components selected



from the group comprising acrylic acids, alkyl acrylates, methacrylates, copolymerizable secondary monomers or monomers with functional groups. Examples of monomers include, but are not limited to, acrylic acid, methacrylic acid, methoxyethyl acrylate, ethyl acrylate, butyl acrylate, butyl methacrylate, 5 hexyl acrylate, hexyl methacrylate, 2-ethylbutyl acrylate, 2-ethylbutyl methacrylate, isooctyl acrylate, isooctyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacrylate, hydroxyethyl acrylate, hydroxypropyl acrylate, acrylamide, dimethylacrylamide, acrylonitrile, 10 dimethylaminoethyl acrylate, dimethylaminoethyl methacrylate, tert-butylaminoethyl acrylate, tert-butylaminoethyl methacrylate, methoxyethyl acrylate, methoxyethyl methacrylate, and the like. Additional examples of appropriate acrylic adhesives suitable in the practice of the invention are described in Satas, "Acrylic Adhesives," Handbook of pressure-Sensitive 15 Adhesive Technology, 2nd ed., pp. 396-456 (D. Satas, ed.), Van Nostrand Reinhold, New York (1989). The acrylic adhesives are commercially available (National Starch and Chemical Corporation, Bridgewater, NJ; Solutia, MA). Further examples of polyacrylate-based adhesives are as follows, identified as product numbers, manufactured by National Starch (Product Bulletin, 2000): 20 87-4098, 87-2287, 87-4287, 87-5216, 87-2051, 87-2052, 87-2054, 87-2196, 87-9259, 87-9261, 87-2979, 87-2510, 87-2353, 87-2100, 87-2852, 87-2074, 87-2258, 87-9085, 87-9301 and 87-5298.

**[00051]** The acrylic polymers comprise cross-linked and non-cross-linked 25 polymers. The polymers are cross-linked by known methods to provide the desired polymers. In preferred embodiments, the adhesive is a polyacrylate adhesive having a glass transition temperature ( $T_g$ ) less than  $-10^\circ\text{C}$ , more preferably having a  $T_g$  of about  $-20^\circ\text{C}$  to about  $-30^\circ\text{C}$ . The molecular weight of the polyacrylate adhesive, expressed as weight average (MW), generally 30 ranges from 25,000 to 10,000,000, preferably from 50,000 to about 3,000,000 and more preferably from 100,000 to 1,000,000 prior to any cross-linking reactions. Upon cross-linking the MW approaches infinity, as known to those involved in the art of polymer chemistry.



[00052] As discussed above, the reservoir 3 comprises a single phase polymeric composition, free of undissolved components, containing an amount of the drug sufficient to induce and maintain analgesia in a human for at least three days. The drug is selected from a group consisting of fentanyl and  
5 analogs thereof, such as, alfentanil, carfentanil, lofentanil, remifentanil, sufentanil, trefentanil, and the like. In preferred embodiments, the drug reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of the drug; preferably about 0.07 to about 1.50 mg/cm<sup>2</sup> of the drug; preferably about 0.08 to about 1.25 mg/cm<sup>2</sup> of the drug; more preferably about 0.09 to about 1.0 mg/cm<sup>2</sup> of  
10 the drug; more preferably about 0.1 to about 0.75 mg/cm<sup>2</sup> of the drug; and even more preferably about 0.12 to about 0.5 mg/cm<sup>2</sup> of the drug. The drug should be soluble in the polymer forming reservoir 3 in a form that is as discussed below. In preferred embodiments, the drug is in the base form and the preferred drugs are fentanyl or sufentanil. In particularly preferred  
15 embodiments, the drug reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of fentanyl; preferably about 0.07 to about 1.50 mg/cm<sup>2</sup> of fentanyl; preferably about 0.08 to about 1.25 mg/cm<sup>2</sup> of fentanyl; more preferably about 0.09 to about 1.0 mg/cm<sup>2</sup> of fentanyl; more preferably about 0.1 to about 0.75 mg/cm<sup>2</sup> of fentanyl; and even more preferably about 0.12 to about 0.5 mg/cm<sup>2</sup> of  
20 fentanyl; wherein fentanyl is in a base form and is completely dissolved. In additionally preferred embodiments, the drug reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of sufentanil; preferably about 0.07 to about 1.50 mg/cm<sup>2</sup> of sufentanil; preferably about 0.08 to about 1.25 mg/cm<sup>2</sup> of sufentanil; more preferably about 0.09 to about 1.0 mg/cm<sup>2</sup> of sufentanil; more  
25 preferably about 0.1 to about 0.75 mg/cm<sup>2</sup> of sufentanil; more preferably about 0.12 to about 0.5 mg/cm<sup>2</sup> of sufentanil; and even more preferably about 0.25 to about 0.4 mg/cm<sup>2</sup> of sufentanil; wherein sufentanil is in a base form and is completely dissolved.

30 [00053] The material forming the reservoir 3 has a solubility for the drug of about 1 wt% to about 25 wt% of the total polymer composition; preferably about 2 wt% to about 15 wt%; more preferably about 4 wt% to about 12 wt% of the total polymer composition; and even more preferably about 6 wt% to about 10 wt% of the total polymer composition. The reservoir 3, with or



without the adhesive coating 6, has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil); preferably about 0.025 mm (1 mil) to about 0.0875 mm (3.5 mil); more preferably 0.0375 mm (1.5 mil) to about 0.075 mm (3 mil); and even more preferably about 0.04 mm (1.6 mil) to about 0.05 mm (2 mil). In  
5 preferred embodiments, the drug is fentanyl, preferably in the base form, wherein the material forming the reservoir 3 has a solubility for fentanyl of about 1 wt% to about 25 wt% of the total polymer composition; preferably about 3 wt% to about 15 wt%; more preferably about 5 wt% to about 12 wt%; and even more preferably about 7 wt% to about 10 wt% of the total polymer  
10 composition. The reservoir 3, with or without the adhesive coating 6, has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil); preferably about 0.025 mm (1 mil) to about 0.075 mm (3 mil); more preferably 0.0375 mm (1.5 mil) to about 0.0625 (2.5 mil); and even more preferably about 0.04 mm (1.6 mil) to about 0.05 mm (2 mil). In additionally preferred embodiments,  
15 the drug is sufentanil, preferably in the base form, wherein the material forming the reservoir 3 has a solubility for sufentanil of about 1 wt% to about 25 wt% of the total polymer composition; preferably about 3 wt% to about 15 wt%; more preferably about 5 wt% to about 12 wt%; and even more preferably about 7 wt% to about 10 wt% of the total polymer composition. The reservoir  
20 3, with or without the adhesive coating 6, has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil); preferably about 0.025 mm (1 mil) to about 0.075 mm (3 mil); more preferably 0.0375 mm (1.5 mil) to about 0.0625 (2.5 mil); and even more preferably about 0.04mm (1.6 mil) to about 0.5 mm (2 mil).

25

**[00054]** In additional embodiments, the reservoir 3 may optionally contain additional components such as, additives, permeation enhancers, stabilizers, dyes, diluents, plasticizer, tackifying agent, pigments, carriers, inert fillers, antioxidants, excipients, gelling agents, anti-irritants, vasoconstrictors  
30 and other materials as are generally known to the transdermal art, provided that such materials are present below saturation concentration in the reservoir.



[00055] Examples of permeation enhancers include, but are not limited to, fatty acid esters of glycerin, such as capric, caprylic, dodecyl, oleic acids; fatty acid esters of isosorbide, sucrose, polyethylene glycol; caproyl lactic acid; laureth-2; laureth-2 acetate; laureth-2 benzoate; laureth-3 carboxylic acid; laureth-4; laureth-5 carboxylic acid; oleth-2; glyceryl pyroglutamate oleate; glyceryl oleate; N-lauroyl sarcosine; N-myristoyl sarcosine; N-octyl-2-pyrrolidone; lauraminopropionic acid; polypropylene glycol-4-laureth-2; polypropylene glycol-4-laureth-5dimethyl lauramide; lauramide diethanolamine (DEA). Preferred enhancers include, but are not limited to, lauryl pyroglutamate (LP), glyceryl monolaurate (GML), glyceryl monocaprylate, glyceryl monocaprinate, glyceryl monooleate (GMO) and sorbitan monolaurate. Additional examples of suitable permeation enhancers are described, for example, in U.S. Patent Nos.: 5,785,991; 5,843,468; 5,882,676; and 6,004,578.

15

[00056] In certain embodiments, the reservoir comprises diluent materials capable of reducing quick tack, increasing viscosity, and/or toughening the matrix structure, such as polybutylmethacrylate (ELVACITE, manufactured by ICI Acrylics, e.g., ELVACITE 1010, ELVACITE 1020, ELVACITE 20), high molecular weight acrylates, i.e., acrylates having an average molecular weight of at least 500,000, and the like.

[00057] In certain embodiments, a plasticizer or tackifying agent is incorporated in the adhesive composition to improve the adhesive characteristics. Examples of suitable tackifying agents include, but are not limited to, aliphatic hydrocarbons; aromatic hydrocarbons; hydrogenated esters; polyterpenes; hydrogenated wood resins; tackifying resins such as ESCOREZ, aliphatic hydrocarbon resins made from cationic polymerization of petrochemical feedstocks or the thermal polymerization and subsequent hydrogenation of petrochemical feedstocks, rosin ester tackifiers, and the like; mineral oil and combinations thereof.

[00058] The tackifying agent employed should be compatible with the blend of polymers. For example, the styrenic block copolymers can be



formulated with rubber compatible tackifying resins, end-block compatible resins such polymethyl styrene, or plasticizers such as mineral oil. Generally the polymer is about 5-50% of the total adhesive composition, the tackifier is about 30-85% of the total adhesive composition, and the mineral oil is about  
5 2-40% of total adhesive composition.

**[00059]** The patch 1 further comprises a peelable protective layer 5. The protective layer 5 is made of a polymeric material that may be optionally metallized. Examples of the polymeric materials include polyurethane,  
10 polyvinyl acetate, polyvinylidene chloride, polypropylene, polycarbonate, polystyrene, polyethylene, polyethylene terephthalate, polybutylene terephthalate, paper, and the like, and a combination thereof. In preferred embodiments, the protective layer comprises a siliconized polyester sheet.

15 **[00060]** A wide variety of materials which can be used for fabricating the various layers of the transdermal delivery patches according to this invention have been described above. This invention therefore contemplates the use of materials other than those specifically disclosed herein, including those which may hereafter become known to the art to be capable of performing the  
20 necessary functions.

#### Administration of the Drug

**[00061]** On application to the skin, the drug in the drug reservoir 3 of the  
25 transdermal patch 1 diffuses into the skin where it is absorbed into the bloodstream to produce a systemic analgetic effect. The onset of analgesia depends on various factors, such as, potency of the drug, the solubility and diffusivity of the drug in the skin, thickness of the skin, concentration of the drug within the skin application site, concentration of the drug in the drug  
30 reservoir, and the like (see e.g., U.S. Patent No. 4,588,580 for a discussion of relative permeabilities and potencies of fentanyl and analogs thereof). It is preferable that a patient experience an adequate effect within six hours of initial application. However, this is significant only on the initial application. On repeated sequential application, the residual drug in the application site of



the patch is absorbed by the body at approximately the same rate as the drug from the new patch is absorbed into the new application area. Thus the patient should not experience any interruption of analgesia.

5   **[00062]**       The concentration of the drug within the skin application sites are also significant in establishing an upper limit on the size of the transdermal therapeutic patch and, conversely, the lower limit on the usable administration rate. In general, when patch according to this invention is employed, the total amount of drug within the skin application site of the patch ranges from about  
10   0.05 to about 200  $\mu\text{g}/\text{cm}^2$ . When such a patch is removed, the analgesic effect continues until the amount of residual drug in the skin is reduced sufficiently below the minimum effective plasma concentration of the drug. For example, after removal of a fentanyl patch, the serum concentrations of fentanyl decline gradually and reach a 50% reduction in serum levels in  
15   approximately 17 hours (see e.g., the labeling insert for the DURAGESIC® patch). These amounts will vary for other drugs, depending on the solubility of the drug and the size of the patch. For example, the solubility of sufentanil in the epidermis is up to about 25% to about 50% of fentanyl. In view of the high potency of fentanyl and analogs thereof, preferably the amount of drug  
20   solubilized in the skin is maintained at an appropriate level to permit prompt termination of therapy.

**[00063]**       When continuous analgesia is desired the depleted patch would be removed and a fresh patch is applied to a new location. For example, the  
25   patch would be sequentially removed and replaced with a fresh patch at the end of the administration period to provide relief from chronic pain. Since absorption of the drug from the fresh patch into the new application area usually occurs at substantially the same rate as absorption by the body of the residual drug within the previous application site of the patch, blood levels will  
30   remain substantially constant. Additionally, it is contemplated that doses may be increased over time and that concurrent use of other analgesics may occur to deal with breakthrough pain.



[00064] In preferred embodiments, the invention provides for a transdermal patch exhibiting a normalized  $C_{\max}$  ranging from about 3.3 to about 82.5 ng/ml-(mg/h), preferably about 6.6 to about 50 ng/ml-(mg/h), more preferably about 13 to about 40 ng/ml-(mg/h), and even more preferably from about 20 to about 35 ng/ml-(mg/h); and a standardized  $C_{\max}$  ranging from about 0.001 to about 0.2 ng/ml-cm<sup>2</sup>, preferably about 0.005 to about 0.15 ng/ml-cm<sup>2</sup>, more preferably about 0.008 to about 0.1 ng/ml-cm<sup>2</sup>, and even more preferably from about 0.01 to about 0.08 ng/ml-cm<sup>2</sup>. The transdermal patch is about 0.5 to about 150 cm<sup>2</sup>; preferably about 2 to about 100 cm<sup>2</sup>; more preferably about 4 to about 50 cm<sup>2</sup>, and even more preferably about 10 to about 20 cm<sup>2</sup>. On administration over skin the transdermal patch exhibits a steady state drug flux of about 0.1 to about 20 µg/cm<sup>2</sup>/hr; preferably about 0.75 to about 10 µg/cm<sup>2</sup>/hr; preferably about 1 to about 8 µg/cm<sup>2</sup>/hr; more preferably about 1.5 to about 5 µg/cm<sup>2</sup>/hr; more preferably about 2 to about 3 µg/cm<sup>2</sup>/hr, and even more preferably about 1 to about 2.5 µg/cm<sup>2</sup>/hr. Steady-state administration rates obtainable according to this invention range from about 0.1 to about 500 µg/h; preferably about 1 to about 300 µg/h; more preferably about 2 to about 250 µg/h; and even more preferably about 5 to about 200 µg/h.

20

[00065] In additionally preferred embodiments, the invention provides for a transdermal fentanyl patch exhibiting a normalized  $C_{\max}$  ranging from about 3.3 to about 82.5 ng/ml-(mg/h), preferably about 10 to about 62 ng/ml-(mg/h), more preferably from about 16 to about 41 ng/ml-(mg/h), and even more preferably from about 20 to about 35 ng/ml-(mg/h); and a standardized  $C_{\max}$  ranging from about 0.01 to about 0.2 ng/ml-cm<sup>2</sup>, preferably about 0.02 to about 0.15 ng/ml-cm<sup>2</sup>, more preferably from about 0.03 to about 0.1 ng/ml-cm<sup>2</sup>, and even more preferably from about 0.04 to about 0.08 ng/ml-cm<sup>2</sup>. The transdermal fentanyl patch is about 1 to about 150 cm<sup>2</sup>; preferably about 2 to about 125 cm<sup>2</sup>; more preferably about 4 to about 100 cm<sup>2</sup>; more preferably about 5 to about 75 cm<sup>2</sup>, and even more preferably about 5 to about 50 cm<sup>2</sup>. On administration over skin, the transdermal fentanyl patch exhibits a steady state drug flux of about 1 to about 10 µg/cm<sup>2</sup>/hr; preferably about 1.5 to about

30



8  $\mu\text{g}/\text{cm}^2/\text{hr}$ ; more preferably about 2 to about 5  $\mu\text{g}/\text{cm}^2/\text{hr}$ , and even more preferably about 2 to about 3  $\mu\text{g}/\text{cm}^2/\text{hr}$ . Steady-state administration rates obtainable for a fentanyl patch according to this invention range from about 1 to about 300  $\mu\text{g}/\text{h}$ ; preferably about 2 to about 250  $\mu\text{g}/\text{h}$ ; and more preferably  
5 about 5 to about 200  $\mu\text{g}/\text{h}$ .

[00066] In additionally preferred embodiments, the invention provides for a transdermal sufentanil patch exhibiting a normalized  $C_{\text{max}}$  ranging from about 0.04 to about 10 ng/ml-(mg/h), preferably about 1 to about 8 ng/ml-  
10 (mg/h), and more preferably from about 2 to about 5.5 ng/ml-(mg/h), and even more preferably about 2.5 to about 5 ng/ml-(mg/h); and a standardized  $C_{\text{max}}$  ranging from about 0.001 to about 0.05 ng/ml- $\text{cm}^2$ , preferably about 0.005 to about 0.04 ng/ml- $\text{cm}^2$ , more preferably from about 0.0075 to about 0.025 ng/ml- $\text{cm}^2$ , and more preferably from about 0.01 to about 0.02 ng/ml- $\text{cm}^2$ . The  
15 transdermal sufentanil patch is about 0.5 to about 40  $\text{cm}^2$ ; preferably about 1 to about 35  $\text{cm}^2$ ; and more preferably about 2 to about 30  $\text{cm}^2$ . On administration over skin, the transdermal sufentanil patch exhibits a steady state drug flux of about 0.1 to about 10  $\mu\text{g}/\text{cm}^2/\text{hr}$ ; preferably about 0.5 to about 8  $\mu\text{g}/\text{cm}^2/\text{hr}$ ; more preferably about 0.75 to about 6  $\mu\text{g}/\text{cm}^2/\text{hr}$ ; more  
20 preferably about 1 to about 5  $\mu\text{g}/\text{cm}^2/\text{hr}$ ; and even more preferably about 1 to about 2.5  $\mu\text{g}/\text{cm}^2/\text{hr}$ . Steady-state administration rates obtainable for a sufentanil patch according to this invention range from about 0.1 to about 200  $\mu\text{g}/\text{h}$ ; preferably about 0.25 to about 150  $\mu\text{g}/\text{h}$ ; more preferably about 0.5 to about 100  $\mu\text{g}/\text{h}$ ; more preferably about 0.75 to about 50  $\mu\text{g}/\text{h}$ ; and even more  
25 preferably about 1 to about 40  $\mu\text{g}/\text{h}$ .

[00067] Administration is maintained for at least three days, and up to 7 days, with 3-4 day regimen being considered preferable. In preferred  
embodiments, at least 3%, but not more than 40%, of the total amount of the  
30 drug in the patch is administered during approximately the first 24 hours of use; at least 6%, but not more than 50%, of the total amount of the drug is administered during approximately the first 48 hours of use; and at least 10%, but not more than 75%, of the total amount of the drug is administered during



the administration period. In preferred embodiments, the patch is a fentanyl patch wherein at least 5%, but not more than 40%, of the total amount of the drug in the patch is administered during approximately the first 24 hours of use; at least 15%, but not more than 50%, of the total amount of the drug is administered during approximately the first 48 hours of use; and at least 25%, but not more than 75%, of the total amount of the drug is administered during the administration period. In alternative embodiments, the patch is a sufentanil patch wherein at least 3%, but not more than 40%, of the total amount of the drug in the patch is administered during approximately the first 24 hours of use; at least 6%, but not more than 50%, of the total amount of the drug is administered during approximately 48 hours of use; and at least 10%, but not more than 75%, of the total amount of the drug is administered during the administration period.

**[00068]** A preferred embodiment of this invention is a patch that is bioequivalent to the DURAGESIC® fentanyl system. In particular, a monolithic fentanyl patch according to the invention produces substantially the same pharmacokinetic effects (as measured by the area under the blood or plasma drug concentration-time curve (AUC) and the peak plasma concentration ( $C_{max}$ ) of the drug) as compared to the DURAGESIC® transdermal fentanyl system, when studied under similar experimental conditions, as described in greater detail hereinafter.

**[00069]** In additional preferred embodiments, a patch of this invention is pharmacologically equivalent to the DURAGESIC® fentanyl system. In particular, a monolithic sufentanil patch according to the invention produces substantially the same therapeutic effects as compared to the DURAGESIC® transdermal fentanyl system, when studied under similar experimental conditions, as described in greater detail hereinafter.

**[00070]** In general, the standard bioequivalence study is conducted in a crossover fashion in a small number of volunteers, usually with 24 to 36 healthy normal adults. Single doses of the drug containing test product, e.g., transdermal fentanyl patch according to the invention, and reference product,



e.g., DURAGESIC® fentanyl system, are administered and blood or plasma levels of the drug are measured over time. Characteristics of these concentration-time curves, such as the area under the blood or plasma drug concentration-time curve (AUC) and the peak blood or plasma concentration ( $C_{max}$ ) of the drug, are examined by statistical procedures as described in greater detail hereinafter. In general, two one-sided statistical tests are carried out using the log-transformed parameter (AUC and  $C_{max}$ ) from the bioequivalence study. The two one-sided tests are carried out at the 0.05 level of significance and the 90% confidence interval is computed. The test and the reference formulation/composition are considered bioequivalent if the confidence interval around the ratio of the mean (test/reference product) value for a pharmacokinetic parameter is no less than 80% on the lower end and no more than 125% on the upper end.

[00071] Two different products are generally considered to be "pharmacologically equivalent" if they produce substantially the same therapeutic effects when studied under similar experimental conditions, as demonstrated through several in vivo and in vitro methods as described above. Therapeutic effects depend on various factors, such as, potency of the drug, the solubility and diffusivity of the drug in the skin, thickness of the skin, concentration of the drug within the skin application site, concentration of the drug in the drug reservoir, and the like, as described in greater detail hereinafter. In general, pharmacological equivalence is demonstrated using measures such as the peak blood or plasma concentration of the drug normalized for the rate of drug administered (i.e. normalized  $C_{max}$  as defined above) and the peak blood or plasma concentration of the drug standardized per unit area of the active drug delivery area of the system (i.e. standardized  $C_{max}$  as defined above).

[00072] When comparing two different products whose drug administration rate is proportional to the size of the patch, there is no difference if the peak blood or plasma concentration of the drug ( $C_{max}$ ) is normalized for the rate of drug administered, or standardized per unit area of the active drug delivery area of the system, in order to establish bioequivalence or



pharmacological equivalence. However, when comparing two different products having different drug administration rate per unit area, it is necessary to normalize the peak blood or plasma concentration of the drug ( $C_{\max}$ ) on the basis of the rate of drug administered to establish bioequivalence or  
5 pharmacological equivalence.

#### Methods of Manufacture

[00073] The transdermal devices are manufactured according to known methodology. A solution of the polymeric reservoir material, as described  
10 above, is added to a double planetary mixer, followed by addition of desired amounts of the drug, preferably fentanyl or sufentanil, more preferably fentanyl base or sufentanil base, and optionally, a permeation enhancer. Preferably, the polymeric reservoir material is an adhesive polymer, which is  
15 solubilized in an organic solvent, e.g., ethanol, ethyl acetate, hexane, and the like. The mixer is then closed and activated for a period of time to achieve acceptable uniformity of the ingredients. The mixer is attached by means of connectors to a suitable casting die located at one end of a casting/film drying line. The mixer is pressurized using nitrogen to feed solution to the casting  
20 die. Solution is cast as a wet film onto a moving siliconized polyester web. The web is drawn through the lines and a series of ovens are used to evaporate the casting solvent to acceptable residual limits. The dried reservoir film is then laminated to a selected backing membrane and the laminate is wound onto the take-up rolls. In subsequent operations, individual  
25 transdermal patches are die-cut, separated and unit-packaged using suitable pouchstock. Patches are cartoned using conventional equipment. In another process, the drug reservoir can be formed using dry-blending and thermal film-forming using equipment known in the art. Preferably, the materials are dry blended and extruded using a slot die followed by calendering to an  
30 appropriate thickness.

#### Experimental



[00074] Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

5 [00075] Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

[00076] Specific examples of various transdermal patches of the  
10 invention which are capable of administering fentanyl and analogs thereof for extended periods of time will be described in the examples set forth hereinafter. The adhesive-reservoir patches wherein the reservoir comprises a single phase polymeric composition of free undissolved components containing an amount of fentanyl or sufentanil at subsaturation concentration are presently  
15 considered preferable according to our invention. In the following examples all percentages are by weight unless noted otherwise.

#### EXAMPLE 1

20 [00077] Monolithic transdermal patches according to Figure 1 were prepared in 5.5, 11, 22, 33 and 44 cm<sup>2</sup> sizes comprising respectively, 2.2, 4.4, 8.8, 13.2 and 17.6 mg each of fentanyl base.

[00078] A polacrylate adhesive (National Starch 87-2287, 100 g) was  
25 solubilized in a solvent (ethyl acetate, 128 ml). Fentanyl base was added to the polacrylate adhesive solution in amounts sufficient to generate a mixture containing 3.4 wt% of fentanyl in the adhesive solution and stirred to dissolve the drug. The solution was cast into a 2 mil thick reservoir layer and the solvent was evaporated. After solvent evaporation, a 3 mil thick backing layer  
30 comprised of a multilaminate of nonlinear LDPE layer/linear LDPE layer/nonlinear LDPE layer was laminated on to the adhesive drug reservoir layer using standard procedures. Individual patches were die-cut from this laminate in 5.5, 11, 22, 33 and 44 cm<sup>2</sup> sizes comprising respectively, 2.2, 4.4,



8.8, 13.2 and 17.6 mg each of fentanyl, to generate monolithic transdermal patches containing 0.4 mg/cm<sup>2</sup> of fentanyl base.

5

## EXAMPLE 2

[00079] Monolithic transdermal patches according to Figure 1 were prepared in 5.5, 11, 22, 33 and 44 cm<sup>2</sup> sizes comprising respectively, 2.2, 4.4, 8.8, 13.2 and 17.6 mg each of fentanyl base.

10

[00080] A polacrylate adhesive (National Starch 87-4287, 100 g) was solubilized in a solvent (ethyl acetate, 160 ml). Fentanyl base was added to the polacrylate adhesive solution in amounts sufficient to generate a mixture containing 2.8 wt% of fentanyl in the adhesive solution and stirred to dissolve the drug. The solution was cast into a 2 mil thick reservoir layer and the solvent was evaporated. After solvent evaporation, a 1.7 mil thick backing layer comprised of a multilaminate of polyethylene/polyurethane/ polyester layer was laminated on to the adhesive drug reservoir layer using standard procedures. Individual patches were die-cut from this laminate in 5.5, 11, 22, 33 and 44 cm<sup>2</sup> sizes comprising respectively, 2.2, 4.4, 8.8, 13.2 and 17.6 mg each of fentanyl, to generate monolithic transdermal patches containing 0.4 mg/cm<sup>2</sup> of fentanyl base.

15  
20

## EXAMPLE 3

25

[00081] Monolithic transdermal patches were prepared in 5.5, 11, 22, 33 and 44 cm<sup>2</sup> sizes comprising 2.2, 4.4, 8.8, 13.2 and 17.6 mg of fentanyl, respectively, as described in Examples 1 and 2 with the following exceptions. Materials were dry blended, in the absence of ethyl acetate, and extruded using a slot die followed by calendering to an appropriate thickness.

30

## EXAMPLE 4



[00082] Monolithic transdermal patches according to Figure 1 were prepared in 5.2, 10.5, 21, 31.5 and 42 cm<sup>2</sup> sizes comprising respectively, 2, 4, 8, 12 and 16 mg each of fentanyl base. A polacrylate adhesive (National Starch 87-2287, 500 g) and glyceryl monolaurate (GML, 10 g) were dissolved  
5 in a solvent (ethyl acetate, 640 ml). Fentanyl base was added to the polacrylate adhesive solution in amounts sufficient to generate a mixture containing 4 wt% of fentanyl in the adhesive solution and stirred to dissolve the drug. The solution was cast into a 1.8 mil thick reservoir layer, and the solvent was evaporated. After solvent evaporation, a 3 mil thick backing layer  
10 comprised of a multilaminate of nonlinear LDPE layer/linear LDPE layer/nonlinear LDPE layer was laminated on to the adhesive drug reservoir layer using standard procedures. Individual patches were die-cut from this laminate in 5.2, 10.5, 21, 31.5 and 42 cm<sup>2</sup> sizes comprising respectively, 2, 4, 8, 12 and 16 mg each of fentanyl, to generate monolithic transdermal patches  
15 containing 0.35 mg/cm<sup>2</sup> of fentanyl base.

#### EXAMPLE 5

[00083] Monolithic transdermal patches were prepared in 5.2, 10.5, 21,  
20 31.5 and 42 cm<sup>2</sup> sizes comprising respectively, 2, 4, 8, 12 and 16 mg each of fentanyl, as described in Example 4 with the following exceptions. Materials were dry blended, in the absence of ethyl acetate, and extruded using a slot die followed by calendering to an appropriate thickness.

25

#### EXAMPLE 6

[00084] Monolithic transdermal patches were prepared in 2.54 cm<sup>2</sup> sizes comprising respectively, 0.25, 0.5, 0.75, 1.0 and 1.1 mg (corresponding to 2, 4, 6, 8 and 9 wt% respectively) each of sufentanil, and a polacrylate adhesive  
30 (National Starch 87-4287, as described in Examples 1 and 2, above).



**EXAMPLE 7**

[00085] Monolithic transdermal systems were prepared in 2.54 cm<sup>2</sup> sizes comprising 1.1 mg of sufentanil and a permeation enhancer, each system  
5 respectively comprising one of: lauryl pyroglutamate (1.1 mg, 9 wt%), glycerol monocaprylate (1.2 mg, 10 wt%), and glycerol monocaprate (0.625 mg, 5 wt%), as described in Example 6.

[00086] Similarly, monolithic transdermal systems comprising  
10 respectively, 0.25, 0.5, 0.75 and 1.0 mg (corresponding to 2, 4, 6 and 8 wt% respectively) each of sufentanil, and a permeation enhancer are prepared as described above.

**EXAMPLE 8**

15

[00087] The in vitro fentanyl flux studies were conducted using various transdermal fentanyl patches - monolithic fentanyl patches and DURAGESIC<sup>®</sup> fentanyl system. The monolithic fentanyl patches containing 0.4 mg/cm<sup>2</sup> of fentanyl base for a 2.54 cm<sup>2</sup> patch were prepared as described in Example 1.  
20 The comparative transdermal flux is illustrated in Figure 3. The in vitro fentanyl flux studies were conducted using a two-compartment diffusion cell with a section of human cadaver epidermis mounted between the cell halves. A transdermal patch was adhered to one side of the skin and a drug-receiving medium was placed on the receptor-side of the cell. The apparatus was  
25 placed in a water bath maintained at 32 ± 0.3° C. Samples of the receptor medium were collected over a period of 72 hours for HPLC analysis of drug concentration. From a knowledge of the receptor volume, the area of skin exposure, the time interval between samplings and the drug concentration, the rate of fentanyl transport was calculated. The time averaged rate of drug  
30 permeation was approximately 1.5 (±20% RSD) µg/h-cm<sup>2</sup>, which was a mean value of at least four experiments using at least four separate skin donors in triplicate (i.e. n = 12).



[00088] As illustrated in Figure 3, the drug flux from the non-rate controlled, monolithic, subsaturated patch of the invention is greater than the drug flux from the rate controlled, liquid reservoir, DURAGESIC® fentanyl depot patch up to 24 hours. From 24 hours up to 72 hours, the drug flux from the non-rate controlled, monolithic, subsaturated patch of the invention decreases as compared to the drug flux from the rate controlled, liquid reservoir, DURAGESIC® fentanyl depot patch.

#### EXAMPLE 9

[00089] The in vitro fentanyl flux studies were conducted as described in Example 8 using various monolithic fentanyl and sufentanil patches. The monolithic fentanyl patches containing 0.4 mg/cm<sup>2</sup> of fentanyl base and 0.25, 0.5, 0.75, 1.0 and 1.1 mg/cm<sup>2</sup> (corresponding to 2, 4, 6, 8 and 9 wt% respectively) each of sufentanil for a 2.54 cm<sup>2</sup> patch were prepared as described in Examples 1-7. The comparative transdermal flux is illustrated in Figures 4, 5 and 6.

#### EXAMPLE 10

[00090] The in vivo fentanyl flux studies were conducted using various transdermal fentanyl patches - monolithic fentanyl patches as described in Example 1, and DURAGESIC® fentanyl system, and the comparative pharmacokinetic parameters are tabulated in Table 1 and 2 below. The pharmacokinetic parameters of the patches were evaluated as follows.

[00091] The study was a single center, randomized, single-dose, open label, eight-sequence, eight-treatment, three-period crossover study. Healthy adult subjects were randomly assigned to one of 8 treatment sequences. There was a minimum washout period of at least 72 hours and not more than 14 days between treatment arms. The washout period began upon removal of the study systems. Each subject received naltrexone 14 hours before system application and twice daily during application. The system was removed 72 hours after application. Serial blood samples were collected from each



subject during each treatment at pre-dose and 0.5, 1, 2, 3, 5, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 73, 74, 78, 84, and 96 hours post dose. Blood samples were analyzed using radioimmunoassay for fentanyl concentration levels.

5

[00092] The results of the in vivo study are tabulated in Tables 1 and 2. Figure 7 illustrates serum fentanyl concentrations following transdermal application of various fentanyl patches - one application of fentanyl patch (20 cm<sup>2</sup>); two applications of fentanyl patch (40 cm<sup>2</sup>), and DURAGESIC<sup>®</sup> fentanyl system (100 µg/h, 40 cm<sup>2</sup>), up to 96 hours after first administration.

10

TABLE 1

Comparative Pharmacokinetic (PK) Parameters  
for fentanyl patches and DURAGESIC<sup>®</sup> fentanyl system

Dose (µg/h)	Size (cm <sup>2</sup> )	Fentanyl content (mg)	C <sub>max</sub> (ng/ml)	Standardized C <sub>max</sub> (ng/ml-cm <sup>2</sup> )	Normalized C <sub>max</sub> (ng/ml-(mg/h))
DURAGESIC <sup>®</sup>					
25	10	2.5	0.6	0.06	24
50	20	5.0	1.4	0.07	28
75	30	7.5	1.7	0.05	22.7
100	40	10.0	2.5	0.06	25
Transdermal fentanyl patches					
12.5	5.5	2.2	0.33	0.06	26.4
25	11	4.4	0.66	0.06	26.4
50	22	8.8	1.32	0.06	26.4
75	33	13.2	1.98	0.06	26.4
100	44	17.6	2.64	0.06	26.4

15



Table 2  
Mean (CV%<sup>a</sup>) Pharmacokinetic (PK) Parameters for  
Transdermal Fentanyl Patches

PK parameters	DURAGESIC <sup>®</sup> fentanyl patch (100 $\mu\text{g/h}$ ), 40 cm <sup>2</sup> (n=36)	Fentanyl patch <sup>b</sup> 20 cm <sup>2</sup> (n=20)	Fentanyl patch <sup>c</sup> 40 cm <sup>2</sup> (n=19)
C <sub>max</sub> (ng/mL)	2.76 (36.0)	1.32 (44.5)	2.91 (61.0)
T <sub>max</sub> (h)	41.89 (44.93)	30.10 (61.60)	31.37 (54.93)
AUC <sub>0-96</sub> (ng.h/mL)	148.5 (36.3)	73.1 (40.6)	154.6 (42.9)
AUC <sub>inf</sub> (ng.h/mL)	172.7 (38.6)	85.1 (42.8)	166.9 (41.2)
Half-life (h)	20.3 (39.8)	21.1 (29.6)	20.1 (42.6)
Flux Rate ( $\mu\text{g/cm}^2/\text{h}$ )	2.56 (12.9)	2.99 (17.8)	2.94 (19.1)

- 5           a = percent coefficient of variation  
            b = one application of a 20 cm<sup>2</sup> patch  
            c = two applications of 20 cm<sup>2</sup> patches

### EXAMPLE 11

10           **[00093]**       The in vivo fentanyl flux studies were conducted using various  
transdermal fentanyl patches - monolithic fentanyl patches as described in  
Example 1, and DURAGESIC<sup>®</sup> fentanyl system, as described in Example 9  
with the following exceptions.

15           **[00094]**       The study was a single center, randomized, single-dose, open  
label, two-sequence, two-treatment, two-period crossover study. Healthy  
adult subjects were randomly assigned to one of two treatment sequences.  
There was a minimum washout period of at least 72 hours and not more than  
20   14 days between treatment arms. The washout period began upon removal of  
the study systems. Each subject received naltrexone 14 hours before system  
application and twice daily during application. The system was removed 72  
hours after application. Serial blood samples were collected from each  
subject during each treatment at pre-dose and 0.5, 1, 2, 3, 5, 8, 12, 18, 24, 30,  
25   36, 42, 48, 54, 60, 66, 72, 73, 74, 78, 84, 96, 108 and 120 hours post dose.  
Blood samples were analyzed using radioimmunoassay for fentanyl  
concentration levels.



[00095] The results of the in vivo study are tabulated in Table 3. Figure 8 illustrates serum fentanyl concentrations following transdermal application of various fentanyl patches - a fentanyl patch of the invention (100  $\mu\text{g/h}$ , 40  $\text{cm}^2$ ), and a DURAGESIC<sup>®</sup> fentanyl system (100  $\mu\text{g/h}$ , 40  $\text{cm}^2$ ), up to 120 hours after first administration. Characteristics of these concentration-time curves, such as the area under the serum drug concentration-time curve (AUC) and the peak blood or plasma concentration ( $C_{\text{max}}$ ) of the drug, were examined by statistical procedures as described earlier. Two one-sided statistical tests were carried out using the log-transformed parameter (AUC and  $C_{\text{max}}$ ) from the in vivo (bioequivalence) study. The two one-sided tests were carried out at the 0.05 level of significance and the 90% confidence interval was computed. The test and the reference formulation/composition were considered bioequivalent if the confidence interval around the ratio of the mean (test/reference product i.e. Treatment B/Treatment A) value for a pharmacokinetic parameter is no less than 80% on the lower end and no more than 125% on the upper end. The results of the statistical analysis of log transformed pharmacokinetic (PK) parameters are tabulated in Table 4.

Table 3

Mean (CV%<sup>a</sup>) Pharmacokinetic (PK) Parameters for  
Transdermal Fentanyl Patches

PK Parameter	DURAGESIC <sup>®</sup> Fentanyl Patch (100 $\mu\text{g/h}$ ) 40 $\text{cm}^2$ (n=33)	Fentanyl Patch (100 $\mu\text{g/h}$ ) 40 $\text{cm}^2$ (n=31)
$C_{\text{max}}$ (ng/mL)	2.86 (39.6)	2.93 (40.7)
$T_{\text{max}}$ (h)	32.2 (49.7)	29.4 (67.4)
$\text{AUC}_{0-120}$ (ng.h/mL)	145.9 (38.1)	154.6 (40.3)
$\text{AUC}_{\text{inf}}$ (ng.h/mL)	159.7 (35.0)	166.8 (37.2)
Half-life (h)	21.2 (28.6)	21.3 (35.3)

a = percent coefficient of variation



Table 4

## Statistical Analysis of Log Transformed Pharmacokinetic (PK) Parameters

Parameter	LnAUC <sub>inf</sub>	LnC <sub>max</sub>
Contrast <sup>a</sup>	Treatment B/Treatment A	Treatment B/Treatment A
N	30	30
Ratio (%)	106.58	98.46
P value	0.068	0.808
Power <sup>b</sup>	>99	92.4
90% Conf. Interval		
Lower	100.67	88.39
Upper	112.84	109.67

<sup>a</sup> Treatment A = DURAGESIC® fentanyl patch (100 µg/h)  
Treatment B = Fentanyl patch (100 µg/h)

<sup>b</sup> The power to detect a difference equal to 20% of the reference mean, at a significance level of 0.05, expressed as a percentage of the reference mean. The reference is the second treatment appearing in each contrast.

[00096] Thus, as evidenced from the results tabulated above and illustrated in Figures 3-8, the monolithic, subsaturated, transdermal patch of the present invention comprising a drug reservoir comprising a single phase polymeric composition comprising a subsaturation concentration of the drug, are bioequivalent products to the rate-controlled, saturated DURAGESIC® fentanyl system. In particular, the monolithic subsaturated patches according to the invention display pharmacokinetic parameters comparable to the transdermal DURAGESIC® fentanyl system.

[00097] The present invention is described and characterized by one or more of the following features and/or characteristics, either alone or in combination with one or more of the other features and characteristics:

[00098] A transdermal patch for administering fentanyl or an analog thereof through the skin comprising: (a) a backing layer; (b) a reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir comprising a single phase polymeric composition free of undissolved components containing an amount of fentanyl or an analog thereof sufficient to induce and maintain analgesia in a human for at least three days and up to seven days; the patch exhibits the patch



exhibits a normalized  $C_{\max}$  ranging from about 3.3 to about 82.5 ng/ml-(mg/h) and a standardized  $C_{\max}$  of about 0.001 to about 0.2 ng/ml-cm<sup>2</sup> and a steady state drug flux of about 0.1 to about 20  $\mu\text{g}/\text{cm}^2/\text{hr}$ . Preferably, the reservoir is formed from an adhesive polymer, more preferably the adhesive is a

5 polyacrylate adhesive. The reservoir comprises a drug selected from the group consisting of fentanyl, alfentanil, lofentanil, remifentanil, sufentanil and trefentanil. Preferably, the drug is in the base form, and the preferred drug is fentanyl or sufentanil. The drug reservoir comprises a polymer having a solubility for fentanyl and analogs thereof of about 1 wt% to about 25 wt%;

10 about 0.05 to about 1.75 mg/cm<sup>2</sup> of fentanyl or analogs thereof; and has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil). The reservoir optionally comprises an enhancer. The patch comprises a backing layer comprising a polymer selected from the group consisting of polyurethane, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene

15 terephthalate (PET), PET-polyolefin laminates, and polybutylene terephthalate, preferably low density polyethylene (LDPE) materials; wherein the backing layer has a thickness of about 2 mil to about 5 mil. Preferably, the drug is in the base form and the preferred drug is fentanyl, wherein fentanyl has a solubility of 7 wt% to 12 wt% in the reservoir; the reservoir is formed

20 from an adhesive, preferably a polyacrylate adhesive, more preferably a polyacrylate adhesive having a  $T_g$  less than -10 °C. In preferred embodiments, the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of fentanyl base; preferably about 0.07 to about 1.50 mg/cm<sup>2</sup> of fentanyl base; preferably about 0.08 to about 1.25 mg/cm<sup>2</sup> of fentanyl base; more preferably

25 about 0.09 to about 1.0 mg/cm<sup>2</sup> of fentanyl base; more preferably about 0.1 to about 0.75 mg/cm<sup>2</sup> of fentanyl base; and even more preferably about 0.12 to about 0.5 mg/cm<sup>2</sup> of fentanyl base. In alternative preferred embodiments, the drug is in the base form and the preferred drug is sufentanil, wherein sufentanil has a solubility of 1 wt% to 25 wt% in the reservoir; the reservoir is

30 formed from an adhesive, preferably a polyacrylate adhesive, more preferably a polyacrylate adhesive having a  $T_g$  less than -10 °C. In preferred embodiments, the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of sufentanil base; preferably about 0.07 to about 1.50 mg/cm<sup>2</sup> of sufentanil base; preferably about 0.08 to about 1.25 mg/cm<sup>2</sup> of sufentanil base;



preferably about 0.09 to about 1.0 mg/cm<sup>2</sup> of sufentanil base; more preferably about 0.1 to about 0.75 mg/cm<sup>2</sup> of sufentanil base; more preferably about 0.12 to about 0.5 mg/cm<sup>2</sup> of sufentanil base; and even more preferably about 0.25 to about 0.4 mg/cm<sup>2</sup> of sufentanil base.

5

[00099] A transdermal patch for administering fentanyl and analogs thereof through the skin comprising (a) a backing layer; (b) a reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir comprising a single phase polymeric composition free of undissolved components containing an amount of fentanyl or an analog thereof sufficient to induce and maintain analgesia in a human for at least three days; wherein the patch is bioequivalent or pharmacologically equivalent to DURAGESIC<sup>®</sup> transdermal fentanyl system; the patch exhibits a normalized C<sub>max</sub> ranging from about 3.3 to about 82.5 ng/ml-(mg/h) and a standardized C<sub>max</sub> of about 0.001 to about 0.2 ng/ml-cm<sup>2</sup> and a steady state drug flux of about 0.1 to about 20 µg/cm<sup>2</sup>/hr. Preferably, the drug is in the base form and the preferred drug is fentanyl, wherein fentanyl has a solubility of 7 wt% to 12 wt% in the reservoir; the reservoir is formed from an adhesive, preferably a polyacrylate adhesive, more preferably a polyacrylate adhesive having a T<sub>g</sub> less than -10 °C. In preferred embodiments, the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of fentanyl base; preferably about 0.07 to about 1.50 mg/cm<sup>2</sup> of fentanyl base; preferably about 0.08 to about 1.25 mg/cm<sup>2</sup> of fentanyl base; more preferably about 0.09 to about 1.0 mg/cm<sup>2</sup> of fentanyl base; more preferably about 0.1 to about 0.75 mg/cm<sup>2</sup> of fentanyl base; and even more preferably about 0.12 to about 0.5 mg/cm<sup>2</sup> of fentanyl base. In alternative preferred embodiments, the drug is in the base form and the preferred drug is sufentanil, wherein sufentanil has a solubility of 1 wt% to 25 wt% in the reservoir; the reservoir is formed from an adhesive, preferably a polyacrylate adhesive, more preferably a polyacrylate adhesive having a T<sub>g</sub> less than -10 °C. In preferred embodiments, the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of sufentanil base; preferably about 0.07 to about 1.50 mg/cm<sup>2</sup> of sufentanil base; preferably about 0.08 to about 1.25 mg/cm<sup>2</sup> of sufentanil base; more preferably about 0.09 to about 1.0 mg/cm<sup>2</sup> of sufentanil base; more preferably about 0.1 to about 0.75 mg/cm<sup>2</sup> of sufentanil base;



more preferably about 0.12 to about 0.5 mg/cm<sup>2</sup> of sufentanil base; and even more preferably about 0.25 to about 0.4 mg/cm<sup>2</sup> of sufentanil base.

**[000100]** A monolithic transdermal patch for administering fentanyl, comprising an adhesive fentanyl reservoir on a backing layer, said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for fentanyl to contain dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days and up to seven days, wherein fentanyl has a solubility of at least 4 wt% in said reservoir; the reservoir has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil); the patch being completely free from a rate controlling membrane, the patch exhibiting a normalized C<sub>max</sub> ranging from about 3.3 to about 82.5 ng/ml- (mg/h); and a standardized C<sub>max</sub> of about 0.01 to about 0.2 ng/ml-cm<sup>2</sup> and a steady state drug flux of about 1-10 µg/cm<sup>2</sup>/hr; and wherein the patch is bioequivalent to DURAGESIC<sup>®</sup> transdermal fentanyl system.

**[000101]** A monolithic transdermal patch for administering sufentanil, comprising an adhesive sufentanil reservoir on a backing layer, said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for sufentanil to contain dissolved sufentanil in an amount sufficient to induce and maintain analgesia in a human for at least three days and up to seven days, wherein sufentanil has a solubility of at least 5 wt% in said reservoir; the reservoir has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil); the patch being completely free from a rate controlling membrane, the patch exhibiting a normalized C<sub>max</sub> ranging from about 0.04 to about 10 ng/ml- (mg/h); and a standardized C<sub>max</sub> of about 0.001 to about 0.005 ng/ml-cm<sup>2</sup> and a steady state drug flux of about 1 to about 10 µg/cm<sup>2</sup>/hr; and wherein the patch is pharmacologically equivalent to DURAGESIC<sup>®</sup> transdermal fentanyl system.

**[000102]** The above-described exemplary embodiments are intended to be illustrative in all respects, rather than restrictive, of the present invention.



Thus the present invention is capable of many variations in detailed implementation that can be derived from the description contained herein by a person skilled in the art. All such variations and modifications are considered to be within the scope and spirit of the present invention.



## We Claim:

1. A transdermal patch for administering fentanyl or an analog thereof through the skin comprising:
  - 5 (a) a backing layer;
  - (b) a reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir comprising a single phase polymeric composition free of undissolved components containing an amount of fentanyl or an analog thereof sufficient to induce and  
10 maintain analgesia in a human for at least three days.
2. The patch of claim 1 which is bioequivalent to DURAGESIC<sup>®</sup> transdermal fentanyl system.
- 15 3. The patch of claim 1 wherein said reservoir is formed from an adhesive polymer.
4. The patch of claim 1 or claim 3 wherein said patch exhibits a normalized  $C_{\max}$  of about 3.3 to about 82.5 ng/ml-(mg/h).  
20
5. The patch of claim 4 wherein the patch exhibits a steady state drug flux of about 0.1 to about 20  $\mu\text{g}/\text{cm}^2/\text{hr}$ .
6. The patch of claim 1 or claim 3 wherein said patch exhibits a  
25 standardized  $C_{\max}$  of about 0.001 to about 0.2 ng/ml- $\text{cm}^2$ .
7. The patch of claim 6 wherein the patch exhibits a steady state drug flux of about 0.1 to about 20  $\mu\text{g}/\text{cm}^2/\text{hr}$ .
- 30 8. The patch of claim 1 wherein said reservoir comprises an amount of dissolved fentanyl or analog thereof sufficient to induce and maintain analgesia for 3-7 days.



9. The patch of claim 8 wherein fentanyl analog is selected from the group consisting of alfentanil, lofentanil, remifentanil and sufentanil.

10. The patch of claim 8 wherein said reservoir comprises a polymer  
5 having a solubility for fentanyl and analogs thereof of about 1 wt% to about 25 wt%.

11. The patch of claim 8 wherein the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of fentanyl or analogs thereof.

10

12. The patch of claim 8 wherein the reservoir has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil).

13. The patch of claim 3 wherein said adhesive is a polyacrylate adhesive.

15

14. The patch of claim 8 or claim 13 wherein the reservoir further comprises an enhancer.

15. The patch of claim 1 wherein the backing layer comprises a polymer  
20 selected from the group consisting of polyurethane, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene terephthalate (PET), PET-polyolefin laminates, and polybutylene terephthalate.

16. The patch of claim 15 wherein the backing layer has a thickness of  
25 about 0.012 mm (0.5 mil) to about 0.125 mm (5 mil).

17. A transdermal patch for administering fentanyl through the skin comprising:

(a) a backing layer;

30 (b) a reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; said reservoir comprising a single phase polymeric composition free of undissolved components containing an amount of fentanyl sufficient to induce and maintain analgesia in a human for at least three days.



18. The patch of claim 17 which is bioequivalent to DURAGESIC®  
transdermal fentanyl system.

5 19. The patch of claim 17 wherein said reservoir is formed from an  
adhesive.

20. The patch of claim 17 or 19 wherein said patch exhibits a normalized  
 $C_{\max}$  of about 3.3 to about 82.5 ng/ml-(mg/h).

10

21. The patch of claim 17 or 19 wherein said patch exhibits a standardized  
 $C_{\max}$  of about 0.01 to about 0.2 ng/ml-cm<sup>2</sup>.

22. The patch of claim 19 wherein the patch exhibits a steady state drug  
15 flux of about 1 to about 10 µg/cm<sup>2</sup>/hr.

23. The patch of claim 17 wherein said reservoir comprises an amount of  
dissolved fentanyl sufficient to induce and maintain analgesia for about 3 to  
about 7 days.

20

24. The patch of claim 17 wherein fentanyl has a solubility of 7 wt% to 12  
wt% in said reservoir.

25. The patch of claim 23 wherein the reservoir comprises about 0.05 to  
25 about 1.75 mg/cm<sup>2</sup> of fentanyl base.

26. The patch of claim 25 wherein the reservoir comprises about 0.08 to  
about 1.25 mg/cm<sup>2</sup> of fentanyl base.

30 27. The patch of claim 26 wherein the reservoir comprises about 0.1 to  
about 0.75 mg/cm<sup>2</sup> of fentanyl base.

28. The patch of claim 27 wherein the reservoir comprises about 0.12 to  
about 0.5 mg/cm<sup>2</sup> of fentanyl base



29. The patch of claim 23 wherein the reservoir has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil).
- 5 30. The patch of claim 19 wherein said adhesive is a polyacrylate adhesive.
31. The patch of claim 30 wherein said polyacrylate adhesive has a  $T_g$  less than  $-10^\circ\text{C}$ .
- 10 32. The patch of claim 30 wherein the reservoir comprises about 0.05 to about  $1.75\text{ mg/cm}^2$  of fentanyl base.
33. The patch of claim 32 wherein the reservoir comprises about 0.08 to  
15 about  $1.25\text{ mg/cm}^2$  of fentanyl base.
34. The patch of claim 33 wherein the reservoir comprises about 0.1 to about  $0.75\text{ mg/cm}^2$  of fentanyl base.
- 20 35. The patch of claim 34 wherein the reservoir comprises about 0.12 to about  $0.5\text{ mg/cm}^2$  of fentanyl base.
36. The patch of claim 30 wherein the reservoir has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil).
- 25 37. The patch of claim 23 or claim 30 wherein the reservoir further comprises an enhancer.
38. The patch of any one of claims 17, 23 or 30, wherein the backing layer  
30 comprises a polymer selected from the group consisting of polyurethane, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene terephthalate (PET), PET-polyolefin laminates, and polybutylene terephthalate.



39. The patch of claim 38, wherein the backing layer comprises low density polyethylene (LDPE) materials, medium density polyethylene (MDPE) materials or high density polyethylene (HDPE) materials.

5 40. The patch of claim 39, wherein the backing layer comprises low density polyethylene (LDPE) materials.

41. The patch of claim 38 wherein the backing layer has a thickness of about 0.012 mm (0.5 mil) to about 0.125 mm (5 mil).

10

42. A transdermal patch for administering fentanyl, comprising an adhesive fentanyl reservoir on a backing layer; said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for fentanyl to contain  
15 dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch exhibiting a normalized  $C_{\max}$  of about 3.3 to about 82.5 ng/ml-(mg/h).

43. A transdermal patch for administering fentanyl, comprising an adhesive  
20 fentanyl reservoir on a backing layer; said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for fentanyl to contain dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch exhibiting a standardized  $C_{\max}$  of  
25 about 0.01 to about 0.2 ng/ml-cm<sup>2</sup>.

44. The patch of claim 42 or 43 wherein the patch exhibits a steady state drug flux of about 1 to about 10  $\mu\text{g}/\text{cm}^2/\text{hr}$ .

30 45. The patch of claim 42 or 43 wherein said reservoir comprises an amount of dissolved fentanyl sufficient to induce and maintain analgesia for about 3 to about 7 days.



46. The patch of claim 45 wherein said adhesive is a polyacrylate adhesive having a  $T_g$  less than  $-10^\circ\text{C}$ ; and fentanyl has a solubility of at least 4 wt% in said reservoir.

5 47. The patch of claim 46 wherein the adhesive reservoir has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil).

48. The patch of claim 47 wherein the reservoir comprises about 0.05 to about  $1.75\text{ mg/cm}^2$  of fentanyl base.

10

49. The patch of claim 48 wherein the reservoir comprises about 0.08 to about  $1.25\text{ mg/cm}^2$  of fentanyl base.

50. The patch of claim 49 wherein the reservoir comprises about 0.1 to  
15 about  $0.5\text{ mg/cm}^2$  of fentanyl base.

51. A monolithic transdermal patch for administering fentanyl, comprising an adhesive fentanyl reservoir on a backing layer, said reservoir comprising a single phase polymeric composition free of undissolved components  
20 containing a polyacrylate adhesive having sufficient solubility for fentanyl to contain dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch being completely free from a rate controlling membrane, said patch exhibiting a normalized  $C_{\text{max}}$  of about 3.3 to about  $82.5\text{ ng/ml} \cdot (\text{mg/h})$ .

25

52. A monolithic transdermal patch for administering fentanyl, comprising an adhesive fentanyl reservoir on a backing layer, said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for fentanyl to  
30 contain dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch being completely free from a rate controlling membrane, said patch exhibiting a standardized  $C_{\text{max}}$  of about 0.01 to about  $0.2\text{ ng/ml} \cdot \text{cm}^2$ .



53. The patch of claim 51 or 52 wherein said reservoir comprises an amount of dissolved fentanyl sufficient to induce and maintain analgesia for about 3 to about 7 days wherein fentanyl has a solubility of at least 4 wt% in said reservoir; the reservoir has a thickness of about 0.0125 mm (0.5 mil) to  
5 about 0.1 mm (4 mil); and said patch exhibits a steady state drug flux of about 1-10  $\mu\text{g}/\text{cm}^2/\text{hr}$ .

54. The patch of claim 51 or 52 wherein the reservoir comprises about 0.05 to about 1.75  $\text{mg}/\text{cm}^2$  of fentanyl base.

10

55. A transdermal patch for administering sufentanil through the skin comprising:

(a) a backing layer;

(b) a reservoir disposed on the backing layer, at least the skin  
15 contacting surface of said reservoir being adhesive; said reservoir comprising a single phase polymeric composition free of undissolved components containing an amount of sufentanil sufficient to induce and maintain analgesia in a human for at least three days.

20 56. The patch of claim 55 wherein said reservoir is formed from an adhesive.

57. The patch of claim 56 wherein said patch exhibits a normalized  $C_{\text{max}}$  of about 0.04 to about 10  $\text{ng}/\text{ml}$ -( $\text{mg}/\text{h}$ ).

25

58. The patch of claim 56 wherein said patch exhibits a standardized  $C_{\text{max}}$  of about 0.001 to about 0.05  $\text{ng}/\text{ml}\text{-cm}^2$ .

59. The patch of claim 57 or 58 wherein the patch exhibits a steady state  
30 drug flux of about 0.1 to about 10  $\mu\text{g}/\text{cm}^2/\text{hr}$ .

60. The patch of claim 55 wherein said reservoir comprises an amount of dissolved sufentanil sufficient to induce and maintain analgesia for about 3 to about 7 days.



61. The patch of claim 55 wherein sufentanil has a solubility of 1 wt% to 25 wt% in said reservoir.
- 5 62. The patch of claim 61 wherein the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of sufentanil base.
63. The patch of claim 62 wherein the reservoir comprises about 0.08 to about 1.25 mg/cm<sup>2</sup> of sufentanil base.
- 10 64. The patch of claim 63 wherein the reservoir comprises about 0.1 to about 0.75 mg/cm<sup>2</sup> of sufentanil base.
65. The patch of claim 64 wherein the reservoir comprises about 0.12 to  
15 about 0.5 mg/cm<sup>2</sup> of sufentanil base.
66. The patch of claim 60 wherein the reservoir has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil).
- 20 67. The patch of claim 56 wherein said adhesive is a polyacrylate adhesive.
68. The patch of claim 67 wherein said polyacrylate adhesive has a T<sub>g</sub> less than -10 °C.
- 25 69. The patch of claim 66 wherein the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of sufentanil base.
70. The patch of claim 69 wherein the reservoir comprises about 0.08 to  
30 about 1.25 mg/cm<sup>2</sup> of sufentanil base.
71. The patch of claim 70 wherein the reservoir comprises about 0.1 to about 0.75 mg/cm<sup>2</sup> of sufentanil base.



72. The patch of claim 70 wherein the reservoir comprises about 0.12 to about 0.5 mg/cm<sup>2</sup> of sufentanil base.

73. The patch of claim 67 wherein the reservoir has a thickness of about  
5 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil).

74. The patch of claim 60 or 66 wherein the reservoir further comprises an enhancer.

10 75. The patch of any one of claims 55, 60 or 64 wherein the backing layer comprises a polymer selected from the group consisting of polyurethane, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene terephthalate (PET), PET-polyolefin laminates, and polybutylene terephthalate.

15

76. The patch of claim 75, wherein the backing layer comprises low density polyethylene (LDPE) materials, medium density polyethylene (MDPE) materials or high density polyethylene (HDPE) materials.

20 77. The patch of claim 76, wherein the backing layer comprises low density polyethylene (LDPE) materials.

78. The patch of claim 75 wherein the backing layer has a thickness of about 0.012 mm (0.5 mil) to about 0.125 mm (5 mil).

25

79. A transdermal patch for administering sufentanil, comprising an adhesive sufentanil reservoir on a backing layer; said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for sufentanil to  
30 contain dissolved sufentanil in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch exhibiting a normalized C<sub>max</sub> of about 0.04 to about 10 ng/ml-(mg/h).



80. A transdermal patch for administering sufentanil, comprising an adhesive sufentanil reservoir on a backing layer; said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for sufentanil to  
5 contain dissolved sufentanil in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch exhibiting a standardized  $C_{max}$  of about 0.001 to about 0.05 ng/ml-cm<sup>2</sup>.
81. The patch of claim 79 or 80 wherein the patch exhibits a steady state  
10 drug flux of about 0.1 to about 10  $\mu\text{g}/\text{cm}^2/\text{hr}$ .
82. The patch of claim 79 or 80 wherein said reservoir comprises an amount of dissolved sufentanil sufficient to induce and maintain analgesia for about 3 to about 7 days.
- 15 83. The patch of claim 82 wherein said adhesive is a polyacrylate adhesive having a  $T_g$  less than -10 °C; and sufentanil has a solubility of at least 1 wt% in said reservoir.
- 20 84. The patch of claim 83 wherein the adhesive reservoir has a thickness of about 0.0125 mm (0.5 mil) to about 0.1 mm (4 mil).
85. The patch of claim 84 wherein the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of sufentanil base.
- 25 86. The patch of claim 85 wherein the reservoir comprises about 0.08 to about 1.25 mg/cm<sup>2</sup> of sufentanil base.
87. The patch of claim 86 wherein the reservoir comprises about 0.1 to  
30 about 0.5 mg/cm<sup>2</sup> of sufentanil base.
88. A monolithic transdermal patch for administering sufentanil, comprising an adhesive sufentanil reservoir on a backing layer, said reservoir comprising a single phase polymeric composition free of undissolved components



containing a polyacrylate adhesive having sufficient solubility for sufentanil to contain dissolved sufentanil in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch being completely free from a rate controlling membrane, said patch exhibiting a normalized  $C_{\max}$  of  
5 about 0.04 to about 10 ng/ml-(mg/h).

89. A monolithic transdermal patch for administering sufentanil, comprising an adhesive sufentanil reservoir on a backing layer, said reservoir comprising a single phase polymeric composition free of undissolved components  
10 containing a polyacrylate adhesive having sufficient solubility for sufentanil to contain dissolved sufentanil in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch being completely free from a rate controlling membrane, said patch exhibiting a standardized  $C_{\max}$  of about 0.001 to about 0.05 ng/ml-cm<sup>2</sup>.

15

90. The patch of claim 88 or 89 wherein said reservoir comprises an amount of dissolved sufentanil sufficient to induce and maintain analgesia for about 3 to about 7 days wherein sufentanil has a solubility of at least 1 wt% in said reservoir; the reservoir has a thickness of about 0.0125 mm (0.5 mil) to  
20 about 0.1 mm (4 mil); and said patch exhibits a steady state drug flux of about 0.1 to about 10  $\mu\text{g}/\text{cm}^2/\text{hr}$ .

91. The patch of claim 90 wherein the reservoir comprises about 0.05 to about 1.75 mg/cm<sup>2</sup> of sufentanil base.

25

92. The patch of claim 1 which is pharmacologically equivalent to DURAGESIC<sup>®</sup> transdermal fentanyl system.

93. The patch of claim 55 which is pharmacologically equivalent to  
30 DURAGESIC<sup>®</sup> transdermal fentanyl system.



1/5




FIG. 1




FIG. 2



2/5




FIG. 3




FIG. 4



3/5




FIG. 5




FIG. 6



4/5




FIG. 7



5/5




FIG. 8



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/07701

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/70 A61K31/4468

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 588 580 A (GALE ROBERT M ET AL) 13 May 1986 (1986-05-13) cited in the application * col.2, 1.55-60; col.3, 1.1-5; col.8, 1.53-54; Ex. 5; claims 1-58 *	1-93
Y	US 5 613 958 A (KOCHINKE FRANK ET AL) 25 March 1997 (1997-03-25) * col.1, 1.37-42; col.5, 1.53-col.6, 1.14 ; col.8, Table I, last cpd; claim 26 (4) *	1-93
Y	US 5 006 342 A (CLEARY GARY W ET AL) 9 April 1991 (1991-04-09) claims 1,7	1-93
P,Y	US 6 203 817 B1 (JOHNSON JUANITA A ET AL) 20 March 2001 (2001-03-20) * col.8, 1.9; col.9, 1.25-28 *	1-93
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

21 August 2002

Date of mailing of the international search report

30/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Uiber, P



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/07701

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 32153 A (ALZA CORP) 1 July 1999 (1999-07-01) * claim 7; claim 24 *	1-93
A	US 5 750 137 A (CRISOLOGO NIEVES MARZAN ET AL) 12 May 1998 (1998-05-12) claims 1-15	1-93



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/07701

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4588580	A	13-05-1986	AU 565177 B2	10-09-1987
			AU 4452785 A	30-01-1986
			BE 902884 A1	04-11-1985
			BE 905568 A4	02-02-1987
			CA 1245983 A1	06-12-1988
			CH 665351 A5	13-05-1988
			CY 1560 A	22-03-1991
			DE 3526339 A1	30-01-1986
			DE 3546830 C2	20-07-1995
			DE 3546869 A1	01-04-1993
			ES 545366 D0	01-05-1988
			ES 8802276 A1	16-07-1988
			ES 557179 D0	16-08-1987
			ES 8707667 A1	01-11-1987
			FR 2567761 A1	24-01-1986
			GB 2165148 A ,B	09-04-1986
			HK 8191 A	01-02-1991
			IT 1183912 B	22-10-1987
			JP 2547726 B2	23-10-1996
			JP 61037725 A	22-02-1986
			NL 8501979 A	17-02-1986
<hr/>				
US 5613958	A	25-03-1997	NONE	
<hr/>				
US 5006342	A	09-04-1991	US 4906463 A	06-03-1990
			AT 119019 T	15-03-1995
			AU 633500 B2	04-02-1993
			AU 3853089 A	24-11-1989
			CA 1325381 A1	21-12-1993
			DE 68921473 D1	06-04-1995
			DE 68921473 T2	22-06-1995
			DK 241090 A	05-10-1990
			EP 0409910 A1	30-01-1991
			IE 891070 L	08-10-1989
			JP 3504977 T	31-10-1991
			JP 5075727 B	21-10-1993
			KR 9501968 B1	08-03-1995
			NO 904317 A	28-11-1990
			NZ 228637 A	26-10-1990
			PT 90240 A ,B	10-11-1989
			WO 8910108 A1	02-11-1989
			US 5186939 A	16-02-1993
			AT 87202 T	15-04-1993
			AT 124256 T	15-07-1995
			AU 640383 B2	26-08-1993
			AU 5784590 A	01-11-1990
			AU 601528 B2	13-09-1990
			AU 8249887 A	23-06-1988
			CA 1309021 A1	20-10-1992
			DE 3751383 D1	03-08-1995
			DE 3751383 T2	11-01-1996
			DE 3785015 D1	29-04-1993
			DE 3785015 T2	07-10-1993
			EP 0272987 A2	29-06-1988
			EP 0483105 A1	29-04-1992
			ES 2039471 T3	01-10-1993
			ES 2075966 T3	16-10-1995
			GR 3017200 T3	30-11-1995



# INTERNATIONAL SEARCH REPORT

information on patent family members

In ..... lonal Application No

PCT/US 02/07701

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5006342	A		JP 2535731 B2	18-09-1996
			JP 8040937 A	13-02-1996
			JP 2105910 C	06-11-1996
			JP 8016054 B	21-02-1996
			JP 63233916 A	29-09-1988
			PT 86426 A , B	17-01-1989
			PT 101320 A , B	29-07-1994
US 6203817	B1	20-03-2001	NONE	
WO 9932153	A	01-07-1999	AU 1728099 A	12-07-1999
			WO 9932153 A1	01-07-1999
			US 6267984 B1	31-07-2001
US 5750137	A	12-05-1998	AT 183926 T	15-09-1999
			AU 679793 B2	10-07-1997
			AU 7924994 A	18-04-1995
			AU 679794 B2	10-07-1997
			AU 7964794 A	18-04-1995
			CA 2165802 A1	06-04-1995
			CA 2167526 A1	06-04-1995
			DE 69420419 D1	07-10-1999
			DE 69420419 T2	23-12-1999
			EP 0721348 A1	17-07-1996
			EP 0721349 A1	17-07-1996
			JP 9505278 T	27-05-1997
			JP 9505279 T	27-05-1997
			NZ 274711 A	26-11-1996
			NZ 275615 A	26-11-1996
			US 5900250 A	04-05-1999
			WO 9509006 A1	06-04-1995
			WO 9509007 A1	06-04-1995
			US 5686097 A	11-11-1997
			US 5747065 A	05-05-1998
			ZA 9407700 A	21-11-1995